GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Early prostate cancer usually causes no symptoms, but can include blood in the urine or semen. The outlook is often excellent, especially if doctors diagnose it in the early stages. Prostate ...

“Prostate cancer feeds on testosterone,” explains ... ADT includes medications that affect the production of LHRH: LHRH agonists and LHRH antagonists. 2. LHRH agonists and LHRH antagonists ...

Researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer compared with use of DPP-4i. HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use ...

With parenteral delivery, this risk seems to be equivalent to that associated with orchiectomy, LHRH agonists ... supported by the National Cancer Research Network Prostate Cancer UK studies ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to ...

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

Prostate cancer has become England's most common cancer as more men are getting checked. Prostate Cancer UK analysis shows diagnoses of the disease overtook breast cancer in 2022 and 2023.

Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...